An alopecia areata developed under NIV interface.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1996-0014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy.
JAAD Case Rep
February 2025
Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.
Evaluating the psychosocial burden and unmet needs for health care access among older adults with inflammatory skin disease.
JAAD Int
February 2025
Department of Dermatology, University of California San Francisco, San Francisco, California.
Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, 510091, People's Republic of China.
Background: Alopecia areata (AA) is a common autoimmune disease, causes sudden hair loss on the scalp, face, and sometimes other areas of the body. Previous studies have suggested more severe manifestations and higher recurrence rates in children than in adults. Moreover, pediatric AA patients with atopic predisposition often exhibit elevated IgE levels, early onset, and a poor prognosis.
View Article and Find Full Text PDFTrending Psychiatric Comorbidities in Patients with Alopecia Areata in the United States from 2002 to 2019.
J Clin Aesthet Dermatol
January 2025
Dr. Armstrong is with the David Geffen School of Medicine at the University of California, Los Angeles in Los Angeles, California.
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Arch Dermatol Res
January 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
Background: Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!